Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases.

Diamantopoulos AP, Hatemi G.

Rheumatology (Oxford). 2013 Oct;52(10):1923-4. doi: 10.1093/rheumatology/ket130. Epub 2013 Apr 4. No abstract available.

PMID:
23559575
2.

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, Ogata A, Yoshizaki K, Kumanogoh A, Kishimoto T, Tanaka T.

Mod Rheumatol. 2012 Apr;22(2):298-302. doi: 10.1007/s10165-011-0497-5. Epub 2011 Jul 12.

PMID:
21748365
3.

Refractory neuro-Behçet treated by tocilizumab: a case report.

Urbaniak P, Hasler P, Kretzschmar S.

Clin Exp Rheumatol. 2012 May-Jun;30(3 Suppl 72):S73-5. Epub 2012 Sep 27.

PMID:
23020826
4.

Tocilizumab treatment for neuro-Behcet's disease, the first report.

Shapiro LS, Farrell J, Borhani Haghighi A.

Clin Neurol Neurosurg. 2012 Apr;114(3):297-8. doi: 10.1016/j.clineuro.2011.10.024. Epub 2011 Nov 9. No abstract available.

PMID:
22078418
5.

Failure of tocilizumab therapy in a patient with mouth and genital ulcers with inflamed cartilage syndrome complicated by aortic aneurysm.

Terreaux W, Mestrallet S, Fauconier M, Pennaforte JL, Penalba C, Eschard JP, Salmon JH.

Rheumatology (Oxford). 2015 Nov;54(11):2111-3. doi: 10.1093/rheumatology/kev255. Epub 2015 Jul 14. Review. No abstract available.

PMID:
26175469
6.

Tocilizumab may be a potential addition to our weapons against neuro-Behçet's disease.

Borhani Haghighi A, Safari A.

Med Hypotheses. 2008;71(1):156-7. doi: 10.1016/j.mehy.2008.01.011. Epub 2008 Mar 4. No abstract available.

PMID:
18304751
7.

Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease.

Redondo-Pachón MD, Enríquez R, Sirvent AE, Andrada E, Noguera-Pons R, Millán I, Amorós F.

Ren Fail. 2013;35(4):547-50. doi: 10.3109/0886022X.2013.773913. Epub 2013 Mar 11.

PMID:
23472940
8.

New approaches in the treatment of Adamantiades-Behçet's disease.

Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C.

Curr Opin Rheumatol. 2006 Jan;18(1):3-9. Review.

PMID:
16344613
9.

Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab.

Cantarini L, Lopalco G, Vitale A, Coladonato L, Rigante D, Lucherini OM, Lapadula G, Iannone F.

Clin Rheumatol. 2015 Jun;34(6):1141-3. doi: 10.1007/s10067-014-2589-z. Epub 2014 Apr 15.

PMID:
24733249
10.

[Efficacy of adalimumab in Behçet's disease. Description of 6 cases].

Calvo Catalá J, Campos Fernández C, Rueda Cid A, González-Cruz Cervellera MI, Baixauli Rubio A, Pastor Cubillo MD.

Reumatol Clin. 2011 Jul-Aug;7(4):258-61. doi: 10.1016/j.reuma.2010.10.003. Epub 2011 Feb 18. Spanish.

11.

Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab.

Caso F, Iaccarino L, Bettio S, Ometto F, Costa L, Punzi L, Doria A.

Immunol Res. 2013 Jul;56(2-3):390-7. doi: 10.1007/s12026-013-8411-1. Review.

PMID:
23572430
12.

Effects of interferon alpha treatment on the clinical course of refractory Behçet's disease: an open study.

Calgüneri M, Oztürk MA, Ertenli I, Kiraz S, Apraş S, Ozbalkan Z.

Ann Rheum Dis. 2003 May;62(5):492-3. No abstract available.

13.

Successful treatment of Behçet's disease with lenalidomide.

Green J, Upjohn E, McCormack C, Zeldis J, Prince HM.

Br J Dermatol. 2008 Jan;158(1):197-8. Epub 2007 Nov 6. No abstract available.

PMID:
17986298
14.

Effects of interferon-alpha treatment on serum IL-6, IL-8, TNF-alpha and soluble TNF-alpha receptors in Behçet's disease.

Direskeneli H, Fresko I, Hamuryudan V.

Scand J Rheumatol. 2005;34(1):75-6. No abstract available.

PMID:
15903033
15.

Interferon-alpha in the management of patients with Behçet's disease.

Yang DS, Taylor SR, Lightman SL.

Br J Hosp Med (Lond). 2008 Oct;69(10):575-9. Review. No abstract available.

PMID:
18949947
16.

Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN.

Kotter I, Deuter C, Stubiger N, Zierhut M.

J Rheumatol. 2005 Aug;32(8):1633; author reply 1634. No abstract available.

17.

Low dose interferon-alpha to treat Behçet's disease.

Thirion M, Miceli-Richard C, Labetoulle M, Mariette X.

Clin Exp Rheumatol. 2007 Sep-Oct;25(5):791. No abstract available.

PMID:
18078636
18.

Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.

Aikawa NE, Gonçalves C, Silva CA, Gonçalves C, Bonfá E, de Carvalho JF.

Rheumatol Int. 2011 Aug;31(8):1097-9. doi: 10.1007/s00296-009-1276-x. Epub 2009 Dec 11.

PMID:
20012049
19.

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.

Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D; French Behçet Network..

J Autoimmun. 2015 Aug;62:67-74. doi: 10.1016/j.jaut.2015.06.005. Epub 2015 Jul 8.

PMID:
26162757
20.

Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease.

De Cassan C, De Vroey B, Dussault C, Hachulla E, Buche S, Colombel JF.

J Crohns Colitis. 2011 Aug;5(4):364-8. doi: 10.1016/j.crohns.2011.03.006. Epub 2011 Apr 27.

PMID:
21683309

Supplemental Content

Support Center